new glp 1 drugs 2025 GLP-1 Drugs: Pulse Survey (U.S.) How Supply and Demand for
Description
Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes Mellitus
Hypothalamic alterations in neurodegenerative diseases and their relation to abnormal energy metabolism
Some individuals may unintentionally skip meals, reduce protein intake, or fall behind on hydration without noticing at first
Conclusions/interpretation At current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes
30, Sept
They are powerful medications for chronic disease and require medical care, follow-up, and realistic expectations
